Quantcast
Last updated on April 17, 2014 at 21:23 EDT

Latest Degarelix Stories

2014-02-20 08:31:11

LONDON, Feb. 20, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 Summary GBI Research has released the pharmaceutical report "Prostate Cancer Therapeutics Market to 2019 - Rising...

2014-01-07 08:31:48

LOS ANGELES, Jan. 7, 2014 /PRNewswire/ -- Interim results from a clinical trial of Prostate Health Cocktail (PHC®) show promise that OncoNatural's over-the-counter dietary supplement may soon become a widely recognized adjunct treatment for prostate disease. Prostate specific antigen, or PSA, was effectively stabilized in more than 83% of study participants. Equally important, PHC demonstrated far less impact on quality of life and physical wellbeing metrics when compared with traditional...

2013-12-19 08:27:12

In China, a Rapidly Expanding Drug-Treated Population Will Drive 12 Percent Annual Market Growth Through 2017, According to a New Report From Decision Resources BURLINGTON, Mass., Dec. 19, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the prostate cancer drug market will experience robust 10 percent annual growth from 2012 to 2022 in the world's major pharmaceutical markets (United...

2013-11-20 23:27:39

MarketResearchReports.Biz announces addition of new report “Prostate Cancer Therapeutics Market to 2019 ” to its database. Visit: http://www.marketresearchreports.biz/analysis-details/prostate-cancer-therapeutics-market-to-2019-rising-prevalence-and-strong-uptake-of-recent-approvals-to-drive-robust-growth-to-2019. Albany, NY (PRWEB) November 20, 2013 Prostate Cancer Therapeutics Market to 2019 - Rising Prevalence and Strong Uptake of Recent Approvals to Drive Robust Growth to 2019 GBI...

2013-06-04 12:25:31

Event proceeds to provide free prostate health exams in CO DENVER, June 4, 2013 /PRNewswire-USNewswire/ -- The following is being released by Prostate Conditions Education Council: WHAT: This Father's Day, Mac's SET the PACE for Prostate Cancer 5K honors patients, survivors and their family members and provides a fun day of activities for the whole family - all while increasing the awareness of prostate cancer and the importance of early detection. Hosted by the Prostate Cancer...

2012-07-23 22:20:42

LAUSANNE, Switzerland, July 24, 2012 /PRNewswire/ -- Debiopharm Group(TM) (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, today announced the treatment of its first patient in a multicentre, open, non-comparative Phase III study to investigate the efficacy, safety, and pharmacokinetics of two subcutaneous (SC) injections of Debio 8206...

2012-04-09 05:40:35

(Ivanhoe Newswire) -- Do you or someone you know suffer from advanced prostate cancer (CRPC)? A new treatment may be available that can help treat the deadly disease. Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. A drug called galeterone works against CRPC by blocking the androgen receptor, reducing levels of the ligand that binds to the receptor and degrading...

2012-04-05 13:47:02

Lung cancer drug requires monitoring of testosterone levels Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society. Investigators at CU Cancer Center looked at the hormone levels in men with anaplastic lymphoma kinase (ALK) positive advanced non-small cell...

2012-04-02 09:22:59

Phase 1 data presented at AACR Annual Meeting 2012; Study showed no dose limiting toxicities with galeterone; Preliminary efficacy data reported Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that its lead candidate galeterone (TOK-001) was well-tolerated with minimal side effects and demonstrated efficacy in patients with castration-resistant prostate cancer (CRPC) in a Phase 1 study. The data will be...

2012-04-02 09:16:50

Patients with castration-resistant prostate cancer had limited side effects and in many cases a drop in prostate-specific antigen expression with galeterone (TOK-001), a small-molecule oral drug, according to phase I data presented at the AACR Annual Meeting 2012, held here March 31 - April 4. Castration-resistant prostate cancer (CRPC) is an advanced form of prostate cancer that occurs when the disease progresses after treatment with androgen deprivation therapy. Galeterone works against...